Lilly to Present New Cardiometabolic Data on Foundayo, Retatrutide and EloraTZP at EASD 2026
Eli Lilly and Company (NYSE: LLY), the manufacturer of Zepbound® (tirzepatide), Mounjaro® (tirzepatide) and Foundayo® (orforglipron), is set to present a broad range of new data from its cardiometabolic disease portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28 through October 2, 2026, in Milan, Italy.
The company’s presence at EASD 2026 will span multiple therapeutic approaches, including established medicines, oral therapies and investigational treatments targeting different biological pathways involved in obesity and type 2 diabetes. The presentations will include Phase 3 results for retatrutide and orforglipron, data for tirzepatide in diabetes and cardiovascular disease, and clinical findings involving eloraTZP, an investigational combination of eloralintide and tirzepatide.
According to Lilly, the breadth of the data reflects its strategy of developing multiple treatment options for people living with cardiometabolic diseases. The company is positioning its portfolio around different mechanisms and treatment modalities, with the objective of addressing the varied needs of people with obesity, overweight and type 2 diabetes.
“More than a billion people worldwide are living with diabetes or obesity, and meeting their diverse needs requires multiple treatment options based on different mechanisms,” said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health. He added that Lilly has built its portfolio with the goal of addressing the diabetes and obesity epidemics and that the data presented at EASD 2026 will highlight potential next-generation approaches.
Lilly to Host Industry Symposium on Cardiometabolic Disease
In addition to its scientific presentations, Lilly will host an industry symposium titled “Changing the Course of Cardiometabolic Disease” on Monday, September 28, from 10:00 a.m. to 4:00 p.m. CEST.
The symposium will be chaired by Prof. Rachel Batterham, senior vice president, medical innovation and external engagement, Lilly Cardiometabolic Health.
The program will coincide with Lilly’s 150th anniversary and will examine evolving approaches to the treatment of obesity and type 2 diabetes, including the potential role of early intervention. Sessions will address developments in oral therapies as well as emerging mechanisms that could influence the future treatment landscape for cardiometabolic disease.
The company’s EASD program will subsequently feature dedicated sessions for retatrutide, Mounjaro, eloraTZP and Foundayo, alongside oral presentations and posters covering additional clinical and exploratory analyses.
Phase 3 Retatrutide Data to Be Presented
One of the key components of Lilly’s EASD program will be a symposium dedicated to retatrutide on Wednesday, September 30, from 8:30 to 9:30 a.m. CEST.
Retatrutide is an investigational once-weekly triple receptor agonist designed to activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.
The company will present Phase 3 findings from the TRIUMPH-2 study, which evaluated retatrutide in adults with obesity or overweight and type 2 diabetes.
According to Lilly, participants receiving retatrutide achieved substantial reductions in body weight and glycated hemoglobin (A1C). At 80 weeks, average weight loss reached as much as 49.6 pounds, or 22.5 kilograms, equivalent to 20.8% of body weight. A1C reductions reached an average of up to 1.6%.
The findings will provide additional information on the potential of a multi-receptor approach in people who have both excess body weight and type 2 diabetes. Because retatrutide remains investigational, its safety and efficacy for any particular use remain subject to regulatory review.
Mounjaro Data Address Cardiovascular Outcomes
Lilly will also feature Mounjaro (tirzepatide) during an EASD-sponsored symposium on September 30 from 8:30 to 9:30 a.m. CEST.
The session will include findings from SURPASS-CVOT, which evaluated tirzepatide in adults with type 2 diabetes and established cardiovascular disease.
In the study, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide) for the primary cardiovascular outcome, with an 8% lower risk of MACE-3 events. The reported hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01.
Lilly also reported that tirzepatide produced greater reductions in A1C and body weight compared with dulaglutide in the study population.
The cardiovascular findings add to the clinical evidence being presented around tirzepatide, which combines GIP and GLP-1 receptor agonism. The data are particularly relevant to patients with type 2 diabetes who also have established cardiovascular disease, a population in which management of both metabolic and cardiovascular risk is an important component of care.
EloraTZP Brings Amylin-Based Approach to EASD
Another area of focus will be eloraTZP, an investigational combination of eloralintide and tirzepatide.
Lilly will host an EASD-sponsored symposium focused on amylins in diabetes on Wednesday, September 30, from 4:30 to 5:30 p.m. CEST. The session will include Phase 2 results for eloraTZP in adults with obesity or overweight and type 2 diabetes.
Additional data will be presented in oral and poster sessions, including Phase 1 findings examining eloralintide in combination with tirzepatide.
In the Phase 1 analysis, adding 3 mg of eloralintide to 5 mg of tirzepatide resulted in 17% weight loss after 16 weeks, compared with 10% among participants receiving tirzepatide 5 mg alone.
The results provide early clinical evidence for combining different mechanisms to address body weight and metabolic disease. Further development will be required to determine the potential role of the combination and to establish its longer-term efficacy and safety.
Foundayo Phase 3 Program Takes Center Stage
Lilly will present Phase 3 data for Foundayo (orforglipron) during an EASD-sponsored symposium on Thursday, October 1, from 8:30 to 9:15 a.m. CEST.
Foundayo is an oral treatment based on orforglipron, and Lilly will highlight findings from the ACHIEVE Phase 3 program evaluating the medicine in adults with type 2 diabetes.
Among the featured studies is ACHIEVE-4, which evaluated Foundayo against insulin glargine in adults with type 2 diabetes and obesity or overweight who were at increased cardiovascular risk.
According to Lilly, Foundayo demonstrated non-inferiority to insulin glargine, with a reported 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events. The hazard ratio for MACE-4 was 0.84, with a 95.0% confidence interval of 0.59 to 1.20, while the hazard ratio for MACE-3 was 0.77, with a 95.0% confidence interval of 0.52 to 1.13.
The company will also present additional analyses from the Foundayo development program.
Oral Orforglipron Data Explore Treatment Goals
Among the additional Foundayo presentations will be a time-to-goal analysis from ACHIEVE-2 and ACHIEVE-3.
The analysis examined how quickly patients treated with Foundayo 17.2 mg reached predefined A1C and body weight reduction goals compared with individuals receiving dapagliflozin or oral semaglutide at doses of 7 mg and 14 mg.
Lilly reported that Foundayo 17.2 mg helped adults with type 2 diabetes reach their A1C and weight-loss goals faster than the comparator treatments in the analysis.
Another presentation from the ATTAIN-1 study will examine physical and psychosocial functioning. In adults with obesity or overweight and at least one weight-related medical condition, Foundayo was associated with improvements in both physical and psychosocial functioning compared with placebo.
These findings broaden the scope of the clinical outcomes being examined beyond measures such as A1C and body weight, addressing how changes in metabolic health may relate to patients’ physical capabilities and psychosocial well-being.
Additional Tirzepatide Findings Include Proteomics and Early Diabetes
Lilly will also present additional findings from the Zepbound and Mounjaro clinical programs.
An exploratory analysis from SURMOUNT-5 will examine changes in the plasma proteome among people receiving Zepbound at doses of 10 mg and 15 mg compared with semaglutide at doses of 1.7 mg and 2.4 mg.
According to Lilly, the two treatments were associated with distinct changes in plasma proteins. The company said the findings could provide biological insights into differences in cardiometabolic effects observed between tirzepatide and semaglutide in the head-to-head SURMOUNT-5 trial.
Another presentation, a prespecified analysis from SURPASS-EARLY, will focus on markers of beta-cell function and insulin sensitivity in people with early type 2 diabetes. Lilly reported that Mounjaro improved these measures in the study population.
The company will also present Phase 4 findings from T-RAM, which examined Mounjaro use among adults with type 2 diabetes during Ramadan fasting. The data indicate that participants receiving tirzepatide were able to maintain glycemic control, while the treatment was generally well tolerated during the fasting period.
Broader Cardiometabolic Strategy
Taken together, Lilly’s EASD 2026 program demonstrates the breadth of its cardiometabolic development strategy, ranging from established therapies such as Mounjaro and Zepbound to the oral medicine Foundayo and investigational programs including retatrutide and eloraTZP.
The presentations cover multiple dimensions of cardiometabolic health, including blood glucose control, weight reduction, cardiovascular outcomes, insulin sensitivity, beta-cell function, physical functioning and psychosocial well-being.
The company’s portfolio also reflects an increasing focus on treatment options based on different mechanisms and delivery methods. Tirzepatide targets both GIP and GLP-1 pathways, retatrutide adds glucagon receptor activity to GIP and GLP-1 agonism, while eloraTZP combines eloralintide with tirzepatide. Foundayo represents Lilly’s development of an oral approach within the incretin treatment landscape.
As Lilly prepares to present these findings at EASD 2026, the company is using the meeting to highlight both the current clinical experience with its marketed medicines and the potential of its next generation of cardiometabolic therapies. The data will provide researchers and healthcare professionals with additional information across diabetes, obesity and cardiovascular risk, while ongoing clinical and regulatory evaluations will determine how the investigational programs may ultimately fit into future treatment strategies.
About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity.
About Mounjaro (tirzepatide) injection
Mounjaro (tirzepatide), the #1 prescribed branded type 2 diabetes medicine for adults in the U.S., is an injectable medicine for adults and children 10 years of age and older with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). In adults with type 2 diabetes who are at high risk for cardiovascular events, Mounjaro is also indicated to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body’s receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
About Foundayo (orforglipron)
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.2 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
About retatrutide
Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials.
About eloralintide
Eloralintide is an investigational once-weekly, selective amylin receptor agonist previously known as LY3841136. Eloralintide has the potential to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness. Phase 3 trials of eloralintide for the treatment of obesity and in adults with obesity or overweight with or without type 2 diabetes are currently ongoing. Lilly also conducted a Phase 2 study (NCT06603571) evaluating eloralintide, alone or in combination, with tirzepatide for weight management in adults with obesity or overweight and type 2 diabetes.